Compare NXST & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXST | INDV |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | 2002 | 2014 |
| Metric | NXST | INDV |
|---|---|---|
| Price | $186.48 | $40.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $263.75 | N/A |
| AVG Volume (30 Days) | 378.4K | ★ 1.5M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | ★ 5.09 | 0.69 |
| Revenue | ★ $4,949,000,000.00 | $1,239,000,000.00 |
| Revenue This Year | $11.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $36.01 | $58.73 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $154.47 | $16.99 |
| 52 Week High | $254.30 | $42.81 |
| Indicator | NXST | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 53.44 |
| Support Level | $177.36 | $39.20 |
| Resistance Level | $191.30 | $41.42 |
| Average True Range (ATR) | 6.10 | 1.28 |
| MACD | 0.95 | -0.14 |
| Stochastic Oscillator | 72.64 | 54.81 |
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Assuming its merger with Tegna is affirmed Nexstar's station total would exceed 259 and reach 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).